AstraZeneca: No Talks With Trump On Emergency Use Authorization For COVID-19 Vaccine
Politicization Could Undermine Public Faith In Vaccine
Executive Summary
Reports come as tensions around the independence of the US FDA mount, and data readouts from the first vaccines could emerge before US election day on 3 November.
You may also be interested in...
AstraZeneca's COVID-19 Vaccine On Hold: A Reminder Product Development Is Never Straightforward
AstraZeneca – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event.
Novavax Willing To Submit COVID-19 Vaccine Before Phase III Completed
US FDA Commissioner Hahn’s controversial statement about approval before the end of Phase III has at least one taker, which may concern public health observers.
AstraZeneca, Janssen, Novavax Likely To Be Next ‘Warp Speed’ Vaccines In Phase III
While AstraZeneca’s adenovirus candidate is expected to use Operation Warp Speed’s platform, its start date remains cloaked; the Janssen and Novavax candidates are expected to enter Phase III in September and October, respectively.